scholarly journals Rapamycin rejuvenates oral health in aging mice

eLife ◽  
2020 ◽  
Vol 9 ◽  
Author(s):  
Jonathan Y An ◽  
Kristopher A Kerns ◽  
Andrew Ouellette ◽  
Laura Robinson ◽  
H Douglas Morris ◽  
...  
Keyword(s):  
Oral Health ◽  
Periodontal Disease ◽  
Tooth Extraction ◽  
The Elderly ◽  
Term Treatment ◽  
Oral Microbiome ◽  
Short Term ◽  
Short Term Treatment ◽  
Periodontal Bone Loss ◽  
Bone Inflammation

Periodontal disease is an age-associated disorder clinically defined by periodontal bone loss, inflammation of the specialized tissues that surround and support the tooth, and microbiome dysbiosis. Currently, there is no therapy for reversing periodontal disease, and treatment is generally restricted to preventive measures or tooth extraction. The FDA-approved drug rapamycin slows aging and extends lifespan in multiple organisms, including mice. Here, we demonstrate that short-term treatment with rapamycin rejuvenates the aged oral cavity of elderly mice, including regeneration of periodontal bone, attenuation of gingival and periodontal bone inflammation, and revertive shift of the oral microbiome toward a more youthful composition. This provides a geroscience strategy to potentially rejuvenate oral health and reverse periodontal disease in the elderly.

scholarly journals Rapamycin rejuvenates oral health in aging mice

2019 ◽  
Author(s):  
Jonathan Y. An ◽  
Kristopher A. Kerns ◽  
Andrew Ouellette ◽  
Laura Robinson ◽  
Doug Morris ◽  
...  
Keyword(s):  
Oral Health ◽  
Bone Loss ◽  
Periodontal Disease ◽  
The Elderly ◽  
Term Treatment ◽  
Oral Microbiome ◽  
Short Term ◽  
Short Term Treatment ◽  
Periodontal Bone Loss ◽  
Bone Inflammation

AbstractPeriodontal disease is an age-associated disorder clinically defined by periodontal bone loss, inflammation of the specialized tissues that surround and support the tooth, and microbiome dysbiosis. Currently, there is no therapy for reversing periodontal disease, and treatment is generally restricted to preventive measures or tooth extraction. The FDA-approved drug rapamycin slows aging and extends lifespan in multiple organisms, including mice. Here we demonstrate that short-term treatment with rapamycin rejuvenates the aged oral cavity of elderly mice, including regeneration of periodontal bone, attenuation of gingival and periodontal bone inflammation, and revertive shift of the oral microbiome toward a more youthful composition. This provides a geroscience strategy to potentially rejuvenate oral health and reverse periodontal disease in the elderly.Single Sentence SummaryShort-term treatment with rapamycin reverses periodontal bone loss, attenuates inflammation, and remodels the oral microbiome toward a more youthful state.

scholarly journals Short-term enhancement of motor neuron synaptic exocytosis during early aging extends lifespan in Caenorhabditis elegans

2020 ◽  
Vol 245 (17) ◽  
pp. 1552-1559
Author(s):  
Tsui-Ting Ching ◽  
Yen-Chieh Chen ◽  
Guang Li ◽  
Jianfeng Liu ◽  
X Z Shawn Xu ◽  
...  
Keyword(s):  
Motor Neurons ◽  
Neuromuscular Junctions ◽  
Early Stage ◽  
Functional Decline ◽  
The Elderly ◽  
Term Treatment ◽  
Short Term ◽  
Short Term Treatment ◽  
C Elegans ◽  
Synaptic Exocytosis

Age-related mobility decline is often associated with negative physical and psychological outcomes, such as frailty, in the elderly population. In C. elegans, during the early stage of the aging process, a progressive deficit of synaptic exocytosis in the motor neurons results in a functional decline at the neuromuscular junctions, which eventually leads to degeneration of both neurons and muscles. This age-dependent functional decline can be ameliorated by pharmacological interventions, such as arecoline, a muscarinic AChR agonist known to promote synaptic exocytosis at the neuromuscular junctions. In this study, we found that a short-term treatment of arecoline during the early stage of aging, when the NMJ functional decline begins, not only slows muscle tissue aging, but also extends lifespan in C. elegans. We have also demonstrated that arecoline acts on the GAR-2/PLCβ pathway in the motor neurons to increases longevity. Together, our findings suggest that synaptic transmission in aging motor neurons may serve as a potential target for pharmacological interventions to promote both health span and lifespan, when applied at the early stage aging. Impact statement The functional decline of motor activity is a common feature in almost all aging animals that leads to frailty, loss of independence, injury, and even death in the elderly population. Thus, understanding the molecular mechanism that drives the initial stage of this functional decline and developing strategies to increase human healthspan and even lifespan by targeting this process would be of great interests to the field. In this study, we found that by precisely targeting the motor neurons to potentiate its synaptic releases either genetically or pharmacologically, we can not only delay the functional aging at NMJs but also slow the rate of aging at the organismal level. Most importantly, we have demonstrated that a critical window of time, that is the early stage of NMJs functional decline, is required for the beneficial effects. A short-term treatment within this time period is sufficient to extend the animals’ lifespan.

Next day effects after nighttime treatment with zolpidem: a review

1996 ◽  
Vol 11 (S1) ◽  
pp. 21s-30s ◽  
Author(s):  
M Undén ◽  
B Roth Schechter
Keyword(s):  
Clinical Trials ◽  
Healthy Subjects ◽  
The Elderly ◽  
Term Treatment ◽  
Residual Effects ◽  
Short Term ◽  
Short Term Treatment ◽  
Sedative Hypnotics ◽  
Repeated Dosing

SummaryThe purpose of this review was to analyze the literature for potential next-day residual effects of zolpidem, a non-benzodiazepine hypnotic, following nighttime administration. Based on more than 30 international clinical trials involving more than 2,600 subjects/patients, it can be concluded that at the recommended doses of zolpidem 10 mg for adults and zolpidem 5 mg for the elderly, at single or repeated dosing, in healthy subjects or insomniac patients, zolpidem appears to induce minimal next-day residual effects. As for all sedative hypnotics, zolpidem is indicated for the short-term treatment of insomnia and is recommended to be taken only when the patient is able to get a full night's sleep before resuming usual activities.

Adrenal phenotype in TPIT insufficient animals cannot be restored by short-term treatment with physiological doses of ACTH and N-POMC

2005 ◽  
Vol 113 (S 1) ◽  
Author(s):  
S Klammer ◽  
D Schulte ◽  
M Fassnacht ◽  
S Hahner ◽  
AM Pulichino ◽  
...  
Keyword(s):  
Term Treatment ◽  
Short Term ◽  
Short Term Treatment

scholarly journals KIDNEY INJURY MOLECULE-1 AS AN EARLY AMIKACIN-INDUCED NEPHROTOXICITY MARKER IN PATIENTS WITH SEPSIS HOSPITALIZED IN THE INTENSIVE CARE UNIT

2019 ◽  
pp. 277-279
Author(s):  
TRISNI UNTARI DEWI ◽  
INSTIATY . ◽  
RUDIANTO SEDONO ◽  
GESTINA ALISKA ◽  
MUHAMMAD KHIFZHON AZWAR ◽  
...  
Keyword(s):  
Intensive Care ◽  
Kidney Injury ◽  
Term Treatment ◽  
Short Term ◽  
Short Term Treatment ◽  
Safe Level ◽  
Study Results ◽  
Early Biomarker ◽  
Kidney Injury Molecule 1 ◽  
Trough Plasma

Objective: This study sought to determine the correlation between trough plasma amikacin concentrations and urinary normalized kidney injurymolecule-1 (KIM-1) concentrations as an early biomarker of nephrotoxicity in patients with sepsis who are hospitalized in an intensive care unit.Methods: In this pilot study, 12 patients with sepsis were treated with amikacin 1000 mg/day between May 2015 and September 2015. The correlationbetween trough plasma amikacin concentrations measured after the third dose and the elevation of urinary normalized KIM-1 concentrations afterthe third amikacin dose relative to the first/second dose was evaluated.Results: In total, three patients had trough plasma amikacin concentrations exceeding the safe level (>10 μg/ml). Furthermore, eight patientsdisplayed higher normalized KIM-1 concentrations after third dose than after the first/second dose; however, there was no correlation betweentrough amikacin concentrations and the elevation of urinary normalized KIM-1 concentrations (r=0.3, p=0.3).Conclusion: The study results illustrated that short-term treatment with an amikacin dose of 1000 mg/day was generally safe in patients with sepsis.

Instrumentation in Voice Assessment and Treatment

1997 ◽  
Vol 6 (4) ◽  
pp. 9-16 ◽  
Author(s):  
Alison Behrman ◽  
Robert F. Orlikoff
Keyword(s):  
Clinical Practice ◽  
Scientific Method ◽  
Term Treatment ◽  
Treatment Goals ◽  
Short Term ◽  
Short Term Treatment ◽  
Voice Assessment ◽  
Assessment And Treatment ◽  
Computer Based ◽  
The Voice

Sophisticated, computer-based instrumentation has become increasingly available to the voice clinician. Yet substantial questions remain regarding its clinical necessity and usefulness. A theoretical model based on the scientific method is developed as a framework that can be used to guide the clinician in the selection and application of instrumental measures. Using the process of hypothesis testing, instrumentation is presented as an integral component of clinical practice. The uses of instrumental measures, and their relevance to long- and short-term treatment goals, are addressed. Clinical examples are presented to illustrate the incorporation of instrumentation and the scientific method into assessment and treatment.

Sign in / Sign up

Export Citation Format

Share Document